SEC Filing Analysis: Surgery Partners, Inc. (SGRY)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A former director of Surgery Partners has filed a notice of proposed sale for $532,869 worth of common stock, acquired through a Stock Appreciation Right (SAR) exercise.
• Market Impact: The direct impact of this single transaction is minimal given its small size relative to the company's market capitalization. However, it continues a significant pattern of selling by this insider over the past quarter.

Company Information

Field	Value
Company	Surgery Partners, Inc.
Ticker Symbol	SGRY
CIK	0001638833
Industry	General Medical & Surgical Hospitals

Insider Information

Field	Value
Name	Wayne DeVeydt
CIK	0001321392
Title/Position	former director
Relationship	former director

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-10-22
Transaction Code	S (Sale)
Security Type	common
Shares Involved	25,052
Price Per Share	~$21.27
Total Value	$532,868.91
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$532,868.91
% of Market Cap	0.02%
Shares Transacted	25,052
% of Shares Outstanding	0.02%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a $2.70 billion market capitalization, this transaction of approximately $0.53 million is not financially material.
• Ownership Concentration: The insider's post-transaction ownership is not disclosed, but given the small size of the sale, it is unlikely to significantly alter the overall ownership structure.
• Dilution Impact: The sale itself is not dilutive. The underlying event was a SAR exercise, which is a form of equity compensation. The sale is likely intended to cover the costs associated with the exercise and lock in profits.
• Transaction Significance: The transaction's value represents just 0.02% of the market cap and 0.02% of shares outstanding, placing it well below the threshold for moderate or high significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is too small to exert any meaningful pressure on the stock price. Sales by former directors are common as they liquidate their holdings post-departure and are generally not viewed as a negative signal about the company's future prospects.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is unlikely to cause a noticeable spike in trading volume.
• Sentiment Indicator: Neutral. The market typically discounts sales from former insiders, especially when linked to equity compensation exercises.

Investment Insights

Positive Market Indicators

• The sale is related to a SAR exercise, a routine part of compensation, rather than a discretionary sale based on negative sentiment.

Risk Factors

• This transaction is part of a much larger pattern. The filing discloses that the same insider has sold approximately 890,000 shares for over $19 million in the preceding three months. This consistent and substantial liquidation, even by a former director, could be interpreted as a lack of long-term belief in the company's upside from its current valuation.

Key Takeaways

1. The Form 144 filing signals a proposed sale by a former director, Wayne DeVeydt.
2. The individual transaction is of low significance, representing a tiny fraction of the company's market value and shares outstanding.
3. The most critical context is the insider's status as a former director and the consistent, large-scale selling over the past quarter, suggesting a planned exit from the position.